Catalyst
Slingshot members are tracking this event:
FDA Clears ArQule's (ARQL) Phase 1 Trial of ARQ 531 in Patients with B-Cell Malignancies
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ARQL |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 11, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fda, Phase 1, Arq 531, B-cell Malignancies
